drugset
Drugs / TT-01488
last change Jul 2026 re-read 3 minutes ago

TT-01488

targets BTK via inhibition

Developed for
B-cell neoplasm
Investigated by
TransThera Sciences (Nanjing), Inc.

Trials 2

today NCT05683717 · Ph 1 NCT05275504 · Ph 1
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05683717 Mar 2023 → Oct 2026 expected B-cell neoplasm TransThera Sciences (Nanjing), Inc. Recruiting No outcome recorded
Phase 1 NCT05275504 Jun → Sep 2022 B-cell neoplasm TransThera Sciences (Nanjing), Inc. Unknown No outcome recorded

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2026-07-02 TransThera Sciences (Nanjing), Inc. Regulatory TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤的中国II期临床试验获批开展 transthera.com ↗
公司产品TT-01488片联合含抗CD20单克隆抗体方案治疗套细胞淋巴瘤(MCL)的II期临床试验，已于2026年7月1日获国家药品监督管理局(NMPA)批准。
2025-12-08 TransThera Sciences (Nanjing), Inc. Results 药捷安康在2025年美国血液学会（ASH）年会公布TT-01488治疗套细胞淋巴瘤的更新结果并获壁报展示 transthera.com ↗
10例疗效可评估的非母细胞型MCL患者中，客观缓解率（ORR）为70%，包括4例完全缓解（CR，40%）及3例部分缓解（PR，30%）。
2024-12-10 TransThera Sciences (Nanjing), Inc. Results 【2024 ASH】药捷安康公布新型可逆BTK抑制剂TT-01488 治疗复发或难治性 B 细胞恶性肿瘤患者的I期临床研究结果 transthera.com ↗
此次TT-01488在ASH会议中展示的I期临床研究是一项开放、多中心、剂量递增研究。

All press releases naming this drug 3 releases

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as TT-01488 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05275504 ↗
1

NCT05683717 ↗
Action Inhibit “a non-covalent reversible BTK inhibitor” NCT05275504 ↗
Route Oral “administered orally” NCT05275504 ↗
Target BTK “a non-covalent reversible BTK inhibitor” NCT05275504 ↗